494 OR502, a best-in-class anti-LILRB2 antibody that enhances both innate and adaptive anti-tumor immune responses
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1797384240716840960 |
|---|---|
| author | Peter Probst Kevin Green Huyen Dinh Francisco Zapata Darbie Whitman Tom Graddis Meghan Zuck Ray Fox Myriam N Bouchlaka Tatyana Pisarenko Elsa L Hay Gajendra Naika Jacob Heit Kamal D Puri |
| author_facet | Peter Probst Kevin Green Huyen Dinh Francisco Zapata Darbie Whitman Tom Graddis Meghan Zuck Ray Fox Myriam N Bouchlaka Tatyana Pisarenko Elsa L Hay Gajendra Naika Jacob Heit Kamal D Puri |
| author_sort | Peter Probst |
| collection | DOAJ |
| first_indexed | 2024-03-08T21:32:35Z |
| format | Article |
| id | doaj.art-c3b2b6e20b1c43349d3d7d553ad93c77 |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-03-08T21:32:35Z |
| publishDate | 2023-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-c3b2b6e20b1c43349d3d7d553ad93c772023-12-21T07:25:08ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262023-11-0111Suppl 110.1136/jitc-2023-SITC2023.0494494 OR502, a best-in-class anti-LILRB2 antibody that enhances both innate and adaptive anti-tumor immune responsesPeter Probst0Kevin Green1Huyen Dinh2Francisco Zapata3Darbie Whitman4Tom Graddis5Meghan Zuck6Ray Fox7Myriam N Bouchlaka8Tatyana Pisarenko9Elsa L Hay10Gajendra Naika11Jacob Heit12Kamal D Puri13OncResponse Inc., Seattle, WA, USAOncResponse Inc., Seattle, WA, USAOncResponse Inc., Seattle, WA, USAOncResponse Inc., Seattle, WA, USAOncResponse Inc., Seattle, WA, USAOncResponse Inc., Seattle, WA, USAOncResponse Inc., Seattle, WA, USAOncResponse Inc., Seattle, WA, USAOncResponse Inc., Seattle, WA, USAOncResponse Inc., Seattle, WA, USAOncResponse Inc., Seattle, WA, USAOncResponse Inc., Seattle, WA, USAOncResponse Inc., Seattle, WA, USAOncResponse Inc., Seattle, WA, USA |
| spellingShingle | Peter Probst Kevin Green Huyen Dinh Francisco Zapata Darbie Whitman Tom Graddis Meghan Zuck Ray Fox Myriam N Bouchlaka Tatyana Pisarenko Elsa L Hay Gajendra Naika Jacob Heit Kamal D Puri 494 OR502, a best-in-class anti-LILRB2 antibody that enhances both innate and adaptive anti-tumor immune responses Journal for ImmunoTherapy of Cancer |
| title | 494 OR502, a best-in-class anti-LILRB2 antibody that enhances both innate and adaptive anti-tumor immune responses |
| title_full | 494 OR502, a best-in-class anti-LILRB2 antibody that enhances both innate and adaptive anti-tumor immune responses |
| title_fullStr | 494 OR502, a best-in-class anti-LILRB2 antibody that enhances both innate and adaptive anti-tumor immune responses |
| title_full_unstemmed | 494 OR502, a best-in-class anti-LILRB2 antibody that enhances both innate and adaptive anti-tumor immune responses |
| title_short | 494 OR502, a best-in-class anti-LILRB2 antibody that enhances both innate and adaptive anti-tumor immune responses |
| title_sort | 494 or502 a best in class anti lilrb2 antibody that enhances both innate and adaptive anti tumor immune responses |
| work_keys_str_mv | AT peterprobst 494or502abestinclassantililrb2antibodythatenhancesbothinnateandadaptiveantitumorimmuneresponses AT kevingreen 494or502abestinclassantililrb2antibodythatenhancesbothinnateandadaptiveantitumorimmuneresponses AT huyendinh 494or502abestinclassantililrb2antibodythatenhancesbothinnateandadaptiveantitumorimmuneresponses AT franciscozapata 494or502abestinclassantililrb2antibodythatenhancesbothinnateandadaptiveantitumorimmuneresponses AT darbiewhitman 494or502abestinclassantililrb2antibodythatenhancesbothinnateandadaptiveantitumorimmuneresponses AT tomgraddis 494or502abestinclassantililrb2antibodythatenhancesbothinnateandadaptiveantitumorimmuneresponses AT meghanzuck 494or502abestinclassantililrb2antibodythatenhancesbothinnateandadaptiveantitumorimmuneresponses AT rayfox 494or502abestinclassantililrb2antibodythatenhancesbothinnateandadaptiveantitumorimmuneresponses AT myriamnbouchlaka 494or502abestinclassantililrb2antibodythatenhancesbothinnateandadaptiveantitumorimmuneresponses AT tatyanapisarenko 494or502abestinclassantililrb2antibodythatenhancesbothinnateandadaptiveantitumorimmuneresponses AT elsalhay 494or502abestinclassantililrb2antibodythatenhancesbothinnateandadaptiveantitumorimmuneresponses AT gajendranaika 494or502abestinclassantililrb2antibodythatenhancesbothinnateandadaptiveantitumorimmuneresponses AT jacobheit 494or502abestinclassantililrb2antibodythatenhancesbothinnateandadaptiveantitumorimmuneresponses AT kamaldpuri 494or502abestinclassantililrb2antibodythatenhancesbothinnateandadaptiveantitumorimmuneresponses |